Skip to main content

Haloperidol

Brand names: Haloperidol

Typical Antipsychotic Oral

At a glance

Medicare prescriptions, 2024
755,832
Medicare drug cost
$22.4M
Average cost per prescription
$29.64
Clinicians who prescribed it
20,311

Where it is prescribed

Loading map…

List the prescribers in any state, county, city or ZIP code →

What it is used for

Haloperidol is indicated for use in the management of manifestations of psychotic disorders.

From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)

Boxed warning

WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with…

The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.

Who prescribes it

All prescribers, by place, name or specialty →

Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.

Trend, 2019–2024

Medicare prescriptions rose 13% from 2019 to 2024.

Medicare Part D prescriptions per year, all prescribers
  • 2019827,450
  • 2020925,330
  • 2021941,163
  • 2022936,921
  • 2023935,062
  • 2024938,810

Biggest change by state since 2019

  • Kansas +41%
  • Minnesota +39%
  • Massachusetts +26%
  • Illinois +25%
  • Wisconsin +25%
  • Louisiana (smallest change) −2%
  • Oklahoma (smallest change) +4%

From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.

What it looks like

Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.

Cardinal Health 107, LLC

StrengthLooks likeImprint
5 mgorange round tablet, 9 mm, scored to split in 2MYLAN 327

Upsher-Smith Laboratories, LLC

StrengthLooks likeImprint
0.5 mgwhite round tablet, 6 mm, scored to split in 2AC 151
1 mgwhite round tablet, 7 mm, scored to split in 2AC 152
2 mgpink round tablet, 7 mm, scored to split in 2AC 153
5 mgorange round tablet, 7 mm, scored to split in 2AC 154
10 mgorange round tablet, 10 mm, scored to split in 2AC 155
20 mgorange round tablet, 12 mm, scored to split in 2AC 156

Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.

Industry payments about this drug

No industry payments to clinicians named this drug in 2025.

Recalls and shortages

Not on the FDA drug shortage list.

1 recall since 2020

  • Mar 2021 · Cardinal Health Inc. · Class II
    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

See all recalls →

Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)

Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.